Background
Methods
Database searching and screening process
Inclusion and exclusion criteria
Data extraction and quality assessment
Statistical analysis
In silico analysis of MMP-8
Results
Characteristics of included studies
Author | Year | Origin | Cancer Type | Race | Source | Case | Control | Case | Control |
P
HWE
| Method | Age range | NOS | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C-799 T(rs11225395) | TT | TC | CC | TT | TC | CC | Case | Control | ||||||||||
Tsai | 2018 | Taiwan | Bladder cancer | Asian | PB | 375 | 375 | 37 | 152 | 186 | 38 | 140 | 197 | 0.082 | PCR-RFLP | mean 61.4 | mean 62.9 | 7 |
Hsiao | 2018 | Taiwan | Breast cancer | Asian | PB | 1232 | 1232 | 118 | 466 | 648 | 131 | 468 | 633 | 0.002 | PCR | NA | NA | 7 |
Pei | 2017 | Taiwan | Leukemia | Asian | PB | 266 | 266 | 29 | 98 | 139 | 32 | 105 | 129 | 0.145 | PCR-RFLP | mean 7.0 | mean 8.3 | 7 |
Shen | 2017 | Taiwan | Lung cancer | Asian | PB | 358 | 716 | 40 | 130 | 188 | 92 | 273 | 351 | 0.001 | PCR-RFLP | mean 64.0 | mean 64.8 | 7 |
Hung | 2017 | Taiwan | Oral cancer | Asian | PB | 788 | 956 | 90 | 284 | 414 | 126 | 364 | 466 | < 0.001 | PCR | mean 55.8 | mean 56.6 | 7 |
Arechavaleta | 2014 | Mexico | Ovary cancer | Latin | HB | 51 | 37 | 12 | 24 | 15 | 5 | 26 | 6 | 0.013 | PCR-RFLP | 49 (25–82) | 39 (13–77) | 7 |
Wieczorek | 2013 | Poland | Bladder cancer | Caucasian | HB | 241 | 199 | 44 | 125 | 72 | 38 | 101 | 60 | 0.697 | RT PCR | 66.3 ± 10.6 | 66.1 ± 10.4 | 8 |
Srivastava | 2013 | India | Bladder cancer | Asian | HB | 200 | 200 | 11 | 90 | 99 | 24 | 84 | 92 | 0.478 | PCR-based | 58.5 ± 12.4 | 56.8 ± 10.8 | 8 |
Kim | 2011 | Korea | Gastric cancer | Asian | HB | 148 | 315 | 14 | 67 | 67 | 38 | 127 | 150 | 0.172 | GoldenGate | mean 57.8 | mean 55.2 | 7 |
Debniak | 2011 | Poland | MM | Caucasian | PB | 296 | 290 | 58 | 152 | 86 | 43 | 134 | 113 | 0.750 | TaqMan | mean 56.0 | mean 55.0 | 8 |
Qiu | 2008 | China Mainland | HCa | Asian | HB | 417 | 480 | 81 | 196 | 140 | 80 | 216 | 184 | 0.223 | PCR-RFLP | NA | NA | 8 |
Lys460Thr | CC | CA | AA | CC | CA | AA | ||||||||||||
Tsai | 2018 | Taiwan | Bladder cancer | Asian | PB | 375 | 375 | 3 | 7 | 365 | 4 | 9 | 362 | < 0.001 | PCR-RFLP | mean 61.4 | mean 62.9 | 7 |
Hsiao | 2018 | Taiwan | Breast cancer | Asian | PB | 1232 | 1232 | 7 | 26 | 1199 | 8 | 23 | 1201 | < 0.001 | PCR | NA | NA | 7 |
Pei | 2017 | Taiwan | Leukemia | Asian | PB | 266 | 266 | 0 | 2 | 264 | 0 | 3 | 263 | 0.926 | PCR-RFLP | mean 7.0 | mean 8.3 | 7 |
Shen | 2017 | Taiwan | Lung cancer | Asian | PB | 358 | 715 | 0 | 3 | 355 | 0 | 4 | 711 | 0.940 | PCR-RFLP | mean 64.0 | mean 64.8 | 7 |
Hung | 2017 | Taiwan | Oral cancer | Asian | PB | 788 | 956 | 0 | 7 | 781 | 0 | 10 | 946 | 0.871 | PCR | mean 55.8 | mean 56.6 | 7 |
Lys87Glu | AA | AG | GG | AA | AG | GG | ||||||||||||
Nan | 2008 | USA | Skin Cancer | Caucasian | PB | 206 | 827 | 56 | 104 | 46 | 222 | 409 | 196 | 0.776 | TaqMan | mean 63.4 | mean 64.5 | 7 |
Kader | 2006 | USA | Invasive BCa | Caucasian | HB | 236 | 546 | 61 | 106 | 69 | 115 | 278 | 153 | 0.587 | RT PCR | 65 (21–88) | 64 (24–89) | 7 |
Kader | 2006 | USA | Superficial BCa | Caucasian | HB | 307 | 546 | 70 | 152 | 85 | 115 | 278 | 153 | 0.587 | RT PCR | 65 (21–88) | 64 (24–89) | 7 |
Quantitative synthesis
Variables |
N
| Case/ | OR(95% CI) Ph P | OR(95% CI) Ph P | OR(95% CI) Ph P | OR(95% CI) Ph P | OR(95% CI) Ph P |
---|---|---|---|---|---|---|---|
Control | M-allele vs. W-allele | MM vs. WW | MW vs. WW | MM + MW vs. WW | MM vs. MW + WW | ||
C-799 T | |||||||
Total | 11 | 4372/5066 | 0.98 (0.92–1.04) 0.068 0.429 | 0.94 (0.82–1.07) 0.097 0.362 | 1.00 (0.92–1.09) 0.193 0.992 | 0.98 (0.90–1.07) 0.086 0.666 | 0.94 (0.83–1.07) 0.249 0.348 |
Ethnicity | |||||||
Asian | 8 | 3784/4540 | 0.95 (0.89–1.01) 0.248 0.125 | 0.89 (0.77–1.02) 0.258 0.102 | 0.98 (0.89–1.08) 0.585 0.682 | 0.96 (0.88–1.04) 0.396 0.322 | 0.90 (0.78–1.03) 0.401 0.111 |
Caucasian | 2 | 537/489 | 1.18 (0.99–1.41) 0.082 0.062 | 1.38 (0.95–1.96) 0.105 0.095 | 1.28 (0.97–1.69) 0.201 0.082 | 1.30 (1.00–1.70) 0.115 0.047 | 1.18 (0.85–1.62) 0.236 0.322 |
Latin | 1 | 51/37 | 0.94 (0.52–1.71) - 0.835 | 0.96 (0.23–3.93) - 0.955 | 0.37 (0.12–1.11) - 0.075 | 0.46 (0.16–1.34) - 0.157 | 1.97 (0.63–6.18) - 0.245 |
Cancer Type | |||||||
BCa | 3 | 816/774 | 0.97 (0.83–1.12) 0.286 0.671 | 0.85 (0.61–1.17) 0.142 0.316 | 1.08 (0.87–1.33) 0.837 0.492 | 1.02 (0.84–1.25) 0.582 0.813 | 0.83 (0.61–1.12) 0.151 0.219 |
Other cancers | 8 | 3556/4292 | 0.99 (0.89–1.11) 0.039 0.898 | 0.96 (0.83–1.11) 0.108 0.578 | 0.99 (0.89–1.09) 0.080 0.763 | 1.00 (0.86–1.16) 0.033 0.965 | 0.97 (0.84–1.11) 0.329 0.631 |
Source of control | |||||||
HB | 5 | 1057/1231 | 1.02 (0.90–1.15) 0.297 0.746 | 0.99 (0.76–1.28) 0.123 0.939 | 1.08 (0.90–1.30) 0.193 0.415 | 1.06 (0.89–1.26) 0.341 0.539 | 0.98 (0.77–1.23) 0.082 0.837 |
PB | 6 | 3315/3835 | 0.98 (0.87–1.10) 0.039 0.705 | 0.92 (0.79–1.08) 0.127 0.310 | 0.98 (0.88–1.08) 0.146 0.662 | 0.99 (0.85–1.14) 0.049 0.844 | 0.93 (0.80–1.08) 0.528 0.328 |
Lys460Thr | |||||||
Total | 5 | 3019/3544 | 0.94 (0.67–1.32) 0.905 0.729 | 0.83 (0.36–1.93) 0.859 0.669 | 1.00 (0.66–1.50) 0.904 0.994 | 0.96 (0.67–1.40) 0.886 0.848 | 0.83 (0.36–1.93) 0.866 0.669 |
Ethnicity/source of control | |||||||
Asian/PB | 5 | 3019/3544 | 0.94 (0.67–1.32) 0.905 0.729 | 0.83 (0.36–1.93) 0.859 0.669 | 1.00 (0.66–1.50) 0.904 0.994 | 0.96 (0.67–1.40) 0.886 0.848 | 0.83 (0.36–1.93) 0.866 0.669 |
Cancer Type | |||||||
BCa | 1 | 375/375 | 0.76 (0.37–1.58) - 0.462 | 0.74 (0.17–3.35) - 0.700 | 0.77 (0.28–2.09) - 0.610 | 0.76 (0.33–1.76) - 0.526 | 0.75 (0.17–3.37) - 0.705 |
Other cancers | 4 | 2644/3169 | 1.00 (0.68–1.46) 0.896 0.462 | 0.88 (0.32–2.42) - 0.799 | 1.05 (0.67–1.65) 0.868 0.823 | 1.02 (0.68–1.54) 0.886 0.919 | 0.87 (0.32–2.42) - 0.796 |
Lys87Glu | |||||||
Total | 3 | 749/1919 | 1.05 (0.93–1.18) 0.968 0.430 | 1.11 (0.88–1.42) 0.953 0.377 | 0.96(0.78–1.18) 0.647 0.722 | 1.01 (0.83–1.22) 0.863 0.928 | 1.13 (0.93–1.38) 0.604 0.222 |
Ethnicity | |||||||
Caucasian | 3 | 749/1919 | 1.05 (0.93–1.18) 0.968 0.430 | 1.11 (0.88–1.42) 0.953 0.377 | 0.96 (0.78–1.18) 0.647 0.722 | 1.01 (0.83–1.22) 0.863 0.928 | 1.13 (0.93–1.38) 0.604 0.222 |
Cancer Type | |||||||
BCa | 2 | 543/1092 | 1.06 (0.91–1.22) 0.841 0.458 | 1.13 (0.85–1.51) 0.810 0.398 | 0.92 (0.72–1.17) 0.544 0.496 | 0.98 (0.78–1.23) 0.745 0.875 | 1.20 (0.94–1.53) 0.508 0.152 |
Other cancers | 1 | 206/827 | 1.03 (0.83–1.28) - 0.756 | 1.07 (0.70–1.66) - 0.745 | 1.08 (0.74–1.59) - 0.684 | 1.08 (0.75–1.56) - 0.678 | 1.02 (0.72–1.43) - 0.921 |
Source of control | |||||||
HB | 2 | 543/1092 | 1.06 (0.91–1.22) 0.841 0.458 | 1.13 (0.85–1.51) 0.810 0.398 | 0.92 (0.72–1.17) 0.544 0.496 | 0.98 (0.78–1.23) 0.745 0.875 | 1.20 (0.94–1.530 0.508 0.152 |
PB | 1 | 206/827 | 1.03 (0.83–1.28) - 0.756 | 1.07 (0.70–1.66) - 0.745 | 1.08 (0.74–1.59) - 0.684 | 1.08 (0.75–1.56) - 0.678 | 1.02 (0.72–1.43) - 0.921 |